Egis in the World
Egis’ products reach 100 countries around the world.
Egis ’products reach countries. Our portfolio consists of 653 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.
Learn moreOur activities incorporate all areas of the pharmaceutical value chain
Click here to learn moreInnovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 business year.
Click here to learn moreContinuous modernisations and investment, launch of a new line of business, tree planting, exhibitions, and a short story contest. In 2023 Egis
Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined
The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.